Objective. This study was carried out to evaluate the effectiveness of two newly synthesized bisphosphonates (BPs) [Alendronate(4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP)) and Neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (AHHexBP)], administered orally, in reducing experimentally induced bone loss. Methods. Unilateral sciatic nerve section was performed on the Sprague-Dawley rat to induce osteopenia in one of the hind limbs. Histomorphometric measurements of the tibial trabecular bone and femur ash content determinations were effected to assess the degree of osteopenia. For comparison Chlodronate (dichloromethylene-1-bisphosphonic acid (Cl 2MBP) was employed as the reference drug. Conclusions. The results of this investigation show that both BPs were significantly active in reducing the osteopenic process in the involved limb and were more active than Chlodronate.
|Number of pages||6|
|Journal||Clinical and Experimental Rheumatology|
|Publication status||Published - Nov 1996|
ASJC Scopus subject areas